Open-label, multi-centre dose escalation phase I study to investigate the safety and tolerability of a continuous infusion of the bispecific T-cell engager (BiTE) MT110 in locally advanced, recurrent or metastatic solid tumours which commonly express EpCAM.

Trial Profile

Open-label, multi-centre dose escalation phase I study to investigate the safety and tolerability of a continuous infusion of the bispecific T-cell engager (BiTE) MT110 in locally advanced, recurrent or metastatic solid tumours which commonly express EpCAM.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2015

At a glance

  • Drugs AMG 110 (Primary)
  • Indications Adenocarcinoma; Breast cancer; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms MT110-101
  • Sponsors Amgen
  • Most Recent Events

    • 12 Jan 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 22 Jan 2014 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.
    • 24 Jun 2013 Planned end date changed from 1 Dec 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top